UPDATE 1-Gilead withdraws bladder cancer drug in US after failed trial Adds share movement in paragraph 4, background and details in paragraphs 2,3,5 Oct 18 (Reuters) - Gilead Sciences GILD.O said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients with a type of bladder cancer after consultation with the U.S.

U.S. RESEARCH ROUNDUP-Abbott, Gilead, Roku Oct 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Abbott, Gilead and Roku, on Thursday. HIGHLIGHTS * Abbott ABT.N : JP Morgan raises target price to $135 from $125 * AIG AIG.N : JP Morgan raises to overweight from neutral * Gilead GILD.O : Raymond James raises target price to $95 from $94 * Lendingclub Corp LC.N : KBW raises to outperform from market perform * Roku Inc R

U.S. RESEARCH ROUNDUP-Aflac, Lincoln National, Prudential Financial Oct 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aflac, Lincoln National and Prudential Financial, on Wednesday. HIGHLIGHTS * Aflac Inc AFL.N : TD Cowen initiates coverage with hold rating; price target $102 * Corebridge Financial Inc CRBG.N : TD Cowen initiates coverage with buy rating * Lincoln National Corp LNC.N : TD Cowen initiates coverage

US ships Marburg vaccines to Rwanda after 11 die in outbreak By Philbert Girinema and Chandni Shah KIGALI, Oct 5 (Reuters) - The United States government completed an initial shipment of vaccine doses and therapeutic drugs for Marburg disease to Rwanda on Oct. 4, Thierry Roels, U.S. CDC Country Director in Rwanda told Reuters on Saturday. The U.S. government is also working closely with international partners and Rwanda's ministry of health on the start of clinical trials to evaluate investigati

UPDATE 1-Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda Adds details in paragraph 2, background in paragraphs 4-6 Oct 3 (Reuters) - Gilead Sciences GILD.O said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical Supply for emergency use in response to the Marburg virus outbreak.

Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda Oct 3 (Reuters) - Gilead Sciences GILD.O said on Thursday it would donate about 5,000 vials of its antiviral remdesivir to the Rwanda Medical Supply for emergency use in response to the Marburg virus disease outbreak. Reporting by Mariam Sunny in Bengaluru' Editing by A

BRIEF-Gilead Donates About 5,000 Vials Of Remdesivir For Emergency Use In Response To Marburg Virus Disease In Rwanda Oct 3 (Reuters) - Gilead Sciences Inc GILD.O : GILEAD DONATES REMDESIVIR FOR EMERGENCY USE IN RESPONSE TO MARBURG VIRUS DISEASE IN RWANDA GILEAD - IT WILL DONATE APPROXIMATELY 5,000 VIALS OF REMDESIVIR TO RWANDA MEDICAL SUPPLY Furth

UPDATE 3-Rwanda to start vaccine trials for Marburg disease in a few weeks Adds detail from WHO in paragraphs 5-6, 8 By Philbert Girinema KIGALI, Oct 3 (Reuters) - Rwanda w ill start cinical trials of experimental vaccines and t reatments f or Marburg disease in the next few weeks , its health minister said on Thursday, t o fight the country's first outbreak of the viral fever, which has so far killed 11 people .

PRESS DIGEST- New York Times business news - Oct 3 Oct 3 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - OpenAI, the company behind ChatGPT, said it had completed a $6.6 billion fund-raising deal that nearly doubles the high-profile company's valuation from just nine months ago.

INDIA STOCKS-Indian shares set to open lower, tracking Asian peers Oct 3 (Reuters) - Indian shares are likely to open lower on Thursday, tracking other Asian peers, as investors curb their risk appetite amid an escalation of the Middle East conflict. The GIFT Nifty GIFc1 was trading at 25,701.50 points as of 8:13 a.m. IST, indicating that the NSE Nifty 50 .NSEI will open below its previous close of 25,796.90. Worries of a further escalation in the Middle East intensified after Iran fired ballist

Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries Oct 2 (Reuters) - Gilead Sciences GILD.O said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries. The U.S.-based drugmaker also plans to provide the companies branded version of the drug, lenacapavir, in 18 countries, such as Botswana, Ethiopia and Kenya, until t

UPDATE 2-EU withdraws marketing authorisation for Abbvie's hepatitis C drug Adds background in paragraphs 5 to 7 Oct 1 (Reuters) - The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's ABBV.N hepatitis C drug Exviera at the request of the company. The regulator said it withdrew the authorisation on Sept.

UPDATE 3-Kailera jumps on weight-loss drug bandwagon with $400 mln early-stage funding Adds comments from CEO interview in paragraphs 4 and 8 By Niket Nishant Oct 1 (Reuters) - Kailera Therapeutics launched on Tuesday as the latest startup seeking a slice of the booming market for anti-obesity therapies with a rare $400 million in early-stage funding.

DIARY-U.S. earnings week ahead Sept 27 (Reuters) - Diary of U.S. (.SPX) corporate earnings for the week ahead. ** Please Note - All times given are in U.S. EDT unless otherwise stated ** U.S. EARNINGS Start Date Start Time RIC Company Name Event Name 30-Sep-2024 AMC POCI.O Precision Optics Corporation Inc Q4 2024 Precision Optics Corporation Inc Earnings Release 30-Sep-2024 AMC TRAK Repositrak Inc Q4 2024 Park City Group Inc Earnings Release 30-Sep-2024 10:30 ENS EnerSys EnerSys Tech Talk: Lithi

BRIEF-FDA Says Gilead Issues Voluntary Nationwide Recall Of One Lot Of Veklury For Injection 100 Mg/Vial Sept 23 (Reuters) - FDA: FDA: GILEAD ISSUES VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF VEKLURY (REMDESIVIR) FOR INJECTION 100 MG/VIAL DUE TO THE PRESENCE OF A GLASS PARTICLE FDA: GILEAD PRODUCT RECALLED IS LYOPHILIZED FORM OF VEKLURY FOR INJECTIO

BUZZ-U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were mixed in choppy trading on Thursday after higher-than-expected producer prices data kept a smaller 25-basis point rate cut by the Fed firmly on the table, while Moderna slumped following a downbeat revenue forecast.

BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was little changed on Thursday after hot producer prices data kept a smaller, 25-basis-point interest-rate cut by the Federal Reserve firmly on the table, while vaccine maker Moderna's shares slumped following a downbeat revenue forecast.

BUZZ-Gilead rises as its long-acting HIV drug shows promise compared with daily Truvada ** Shares of drugmaker Gilead GILD.O rise nearly 2% to $82.55 ** Co says its HIV injectable drug lenacapavir reduced HIV infections by 96% and was superior to daily pill Truvada in second late-stage trial ** The study included cisgender men, transgender men, tra

U.S. RESEARCH ROUNDUP-Cintas, Sprouts Farmers Market, Voya Financial Sept 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cintas Corp, Sprouts Farmers market and Voya Financial, on Thursday. HIGHLIGHTS * Ally Financial Inc ALLY.N : RBC cuts target price to $40 from $49 * Cintas Corp CTAS.O : CFRA adjusts target price to $170 from $645 to reflect 4-for-1 stock split * Gilead GILD.O : Raymond James raises target pri

UPDATE 2-US FDA staff questions confirmatory trial data for Intercept's liver disease drug Rewrites paragraph 1, adds details from FDA and company's briefing documents in paragraphs 7, 8 and 9 and background in paragraphs 10 and 11 Sept 11 (Reuters) - Staff reviewers at the U.S. Food and Drug Administration said on Wednesday a confirmatory trial did not show the effectiveness of Intercept's liver disease drug, which received the health regulator's accelerated nod in 2016. Under the accelerated p